Published in Blood Weekly, August 15th, 2002
"Allogeneic hematopoietic stem cell transplantation (HSCT) is associated with prolonged anemia caused by defective erythropoietin (Epo) production," explained Dr. Frederic Baron and colleagues working at the University of Liege in Liege, Belgium.
Although rhEpo treatment provided only limited benefit immediately after HSCT, the recombinant growth factor was highly effective when given at least 1 month after transplantation, Baron and coauthors found.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.